Signal from the log
Vinci Pharmaceuticals
plus de 8 M$ · Series A · United States · Biotech
Vinci Pharmaceuticals développe EPIPLANT, un implant posé sur la paroi externe de l'oeil qui diffuse longtemps un médicament vers la rétine, pour éviter les injections répétées dans l'oeil. La technologie vient du laboratoire de Karl Csaky au Retina Foundation of the Southwest, et un premier essai chez l'humain est prévu en 2027. Série A menée par Dynagrow Capital.
Article
Announced on , logged by the watch of 8 October 2026.
- Operation
- Funding round
- Announced amount
- plus de 8 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Dynagrow Capital , with MintPharma Capital
Provenance
Source prnewswire
Logged on 8 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.